EMIT.F Stock Overview
Develops, produces, and markets therapeutic medical systems for performing non-invasive treatments on the human body in Israel and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Elbit Imaging Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₪1.01 |
| 52 Week High | ₪1.14 |
| 52 Week Low | ₪0.80 |
| Beta | 0.59 |
| 11 Month Change | -11.40% |
| 3 Month Change | 1.00% |
| 1 Year Change | n/a |
| 33 Year Change | -42.29% |
| 5 Year Change | 20.24% |
| Change since IPO | -99.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMIT.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -2.1% |
| 1Y | n/a | 22.4% | 29.6% |
Return vs Industry: Insufficient data to determine how EMIT.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how EMIT.F performed against the US Market.
Price Volatility
| EMIT.F volatility | |
|---|---|
| EMIT.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMIT.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EMIT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Ron Hadassi | n/a |
Elbit Imaging Ltd., together with its subsidiaries, develops, produces, and markets therapeutic medical systems for performing non-invasive treatments on the human body in Israel and internationally. The company offers treatment-oriented medical systems with ultrasound beam and magnetic resonance imaging for noninvasive treatments in human body. It also offers medical products based on stem cells derived primarily from umbilical cord blood and intended for bone marrow transplantation in patients with leukemia or lymph node cancer, non-malignant blood diseases, and metabolic genetic diseases.
Elbit Imaging Ltd. Fundamentals Summary
| EMIT.F fundamental statistics | |
|---|---|
| Market cap | US$14.77m |
| Earnings (TTM) | -US$181.02k |
| Revenue (TTM) | US$87.57k |
168.7x
P/S Ratio-81.6x
P/E RatioIs EMIT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMIT.F income statement (TTM) | |
|---|---|
| Revenue | ₪328.00k |
| Cost of Revenue | ₪0 |
| Gross Profit | ₪328.00k |
| Other Expenses | ₪1.01m |
| Earnings | -₪678.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.064 |
| Gross Margin | 100.00% |
| Net Profit Margin | -206.71% |
| Debt/Equity Ratio | 0% |
How did EMIT.F perform over the long term?
See historical performance and comparison